Eprex erythropoeitin alfa regulatory update

The U.K. Medicines Control Agency posted a safety message regarding 40 cases of pure red cell aplasia (PRCA) in patients treated with Eprex, which is marketed in Europe by JNJ company Janssen-Cilag

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE